TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: ADIC    
Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma

Useful For Suggests clinical disorders or settings where the test may be helpful

Establishing laboratory evidence of disseminated intravascular coagulation

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Initial testing includes prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, D-dimer, and disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF) profile interpretation.

If PT is >13.9 seconds, then PT mix will be performed at an additional charge.

If aPTT is > or =38 seconds, then aPTT mix and dilute Russell viper venom time (dRVVT) will be performed at an additional charge.

If dRVVT ratio is > or =1.20, then dRVVT mix and dRVVT confirmation will be performed at an additional charge.

If fibrinogen is <150 mg/dL, or clinically indicated, then PT-fibrinogen will be performed at an additional charge.

If D-dimer is >500 ng/mL fibrinogen equivalent units (FEU), then soluble fibrin monomer will be performed at an additional charge.

If aPTT mix is > or =38 seconds and TT is <35.0 seconds (no evidence of heparin), then platelet neutralization procedure will be performed at an additional charge.

If TT is > or =25.0 seconds, then reptilase time will be performed at an additional charge.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Disseminated intravascular coagulation (DIC) and intravascular coagulation and fibrinolysis (ICF), collectively termed DIC/ICF is a consumptive hemorrhagic and microthrombotic disorder that manifests as clinical bleeding or thrombosis. Conditions associated with DIC/ICF can include sepsis, trauma (eg, head injury, severe tissue injury), obstetric complications (eg, amniotic fluid embolism, abruptio placentae), malignancies, vascular disorders (eg, hemangiomas, aortic aneurysm), and immunologic disorders.

 

These disorders can cause formation of thrombin and fibrin intravascularly, which can result in widespread fibrin deposition contributing to thrombosis and organ failure or, conversely, can result in bleeding due to consumption of coagulation proteins and platelets. DIC/ICF is not a disease, rather it is a syndrome that is secondary to an underlying disorder.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report is provided.

Interpretation Provides information to assist in interpretation of the test results

An interpretive report will be provided.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

No significant cautionary statements

Clinical Reference Recommendations for in-depth reading of a clinical nature

Boender J, Kruip MJ, Leebeek FWG: A diagnostic approach to mild bleeding disorders. J Thromb Haemost. 2016 Aug;14(8):1507-1516. doi: 10.1111/jth.13368

Special Instructions Library of PDFs including pertinent information and forms related to the test